Innovative Cellular Therapeutics Holdings, Ltd.

Innovative Cellular Therapeutics, Inc.

Koninklijke Philips Corporation N.v.

Synaptics Corporation

Wei Ding

Zhiyuan Cao

Chengfei Pu

Song Liang

Cornelis Reinder Ronda

Lei Zhang

Bo Tong Liu

Zhao Wu

Lei Xiao

Wensheng Wang

Le Tian

Dongqi Chen

Hendrikus Albertus Adrianus Maria De Ruijter

Guanjun Yang

Yuzhe Peng

Christopher Ballas

Sean Patrick Hughes

Xuan Zhu

Vincent Mathieu Vaucelle

Xianyang Jiang

Zhijie Xue

Wen Gu

An input device a touchpad, an near field communication (NFC) controller, and an antenna electrically interfaced with the NFC controller. The antenna includes an antenna rod. The antenna rod is straight and disposed outside a perimeter of the touchpad.

Input device with near-field communication

The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC.

Modified cell and use thereof in gene and cell therapy

Embodiments relate to a modified cell comprising a polynucleotide encoding a dominant negative form of Death receptor 5 (DR5). In embodiments, the modified cell further comprises a chimeric antigen receptor (CAR) and/or a modified TCR.

Modified cell with enhanced functionality and cellular therapy thereof

An input device includes a touchpad and a mounting bracket made of an electrically conductive material and configured to anchor the touchpad in an electronic system. The input device further includes a near field communication (NFC) controller, and an antenna electrically interfaced with the NFC controller. The antenna includes an electrically conductive strip formed by a segment of the mounting bracket.

The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFN&#x3b3;.

Vaccine and uses thereof in cell therapy

Portable reading lamp

Growing community of inventors

Shanghai, China

Wei Ding